The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
The objective of the study is to assess efficacy and safety of a closed loop system (t:slim
 X2 with Control-IQ Technology) in a large randomized controlled trial.
After consent is signed, eligibility will be assessed. Eligible participants not currently
 using an insulin pump and Dexcom CGM with minimum data requirements will initiate a run-in
 phase of 2 to 8 weeks that will be customized based on whether the participant is already a
 pump or CGM user. Participants who skip or successfully complete the run-in will be randomly
 assigned 2:1 to the use of closed-loop control (CLC group) using t:slim X2 with Control-IQ
 Technology vs. SAP for 6 months.
Inclusion Criteria:

 1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
 one year and using insulin for at least 1 year.

 2. Familiarity and use of a carbohydrate ratio for meal boluses.

 3. Age ≥14.0 years old.

 4. For females, not currently known to be pregnant. If female and sexually active, must
 agree to use a form of contraception to prevent pregnancy while a participant in the
 study. A negative serum or urine pregnancy test will be required for all females of
 child-bearing potential. Participants who become pregnant will be discontinued from
 the study. Also, participants who during the study develop and express the intention
 to become pregnant within the timespan of the study will be discontinued.

 5. For participants <18 years old, living with one or more parent/legal guardian
 knowledgeable about emergency procedures for severe hypoglycemia and able to contact
 the participant in case of an emergency.

 6. Willingness to suspend use of any personal CGM for the duration of the clinical trial
 once the study CGM is in use.

 7. Willingness to use a regular insulin pump during the study with no automatic insulin
 adjustment based on glucose level when assigned to participate in an SAP group

 8. Investigator has confidence that the participant can successfully operate all study
 devices and is capable of adhering to the protocol.

 9. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
 and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
 study.

 10. Total daily insulin dose (TDD) at least 10 U/day.

 11. Willingness not to start any new non-insulin glucose-lowering agent during the course
 of the trial.

 Exclusion Criteria

 1. Concurrent use of any non-insulin glucose-lowering agent other than metformin
 (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors,
 sulfonylureas).

 2. Hemophilia or any other bleeding disorder.

 3. A condition, which in the opinion of the investigator or designee, would put the
 participant or study at risk.

 4. Participation in another pharmaceutical or device trial at the time of enrollment or
 during the study.

 5. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc.
 or TypeZero Technologies, LLC, or having a direct supervisor at place of employment
 who is also directly involved in conducting the clinical trial (as a study
 investigator, coordinator, etc.); or having a first-degree relative who is directly
 involved in conducting the clinical trial.